265 related articles for article (PubMed ID: 29930979)
1. siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
Duggan SP; Garry C; Behan FM; Phipps S; Kudo H; Kirca M; Zaheer A; McGarrigle S; Reynolds JV; Goldin R; Kalloger SE; Schaeffer DF; Long A; Strid J; Kelleher D
Cell Mol Gastroenterol Hepatol; 2018; 5(4):569-590. PubMed ID: 29930979
[TBL] [Abstract][Full Text] [Related]
2. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma.
Panda A; Bhanot G; Ganesan S; Bajpai M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885081
[TBL] [Abstract][Full Text] [Related]
4. The Immune Underpinnings of Barrett's-Associated Adenocarcinogenesis: a Retrial of Nefarious Immunologic Co-Conspirators.
Tambunting L; Kelleher D; Duggan SP
Cell Mol Gastroenterol Hepatol; 2022; 13(5):1297-1315. PubMed ID: 35123116
[TBL] [Abstract][Full Text] [Related]
5. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
[TBL] [Abstract][Full Text] [Related]
6. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
7. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
8. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells.
Zhang HY; Zhang Q; Zhang X; Yu C; Huo X; Cheng E; Wang DH; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G454-60. PubMed ID: 21148399
[TBL] [Abstract][Full Text] [Related]
9. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
10. NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells.
Nadatani Y; Huo X; Zhang X; Yu C; Cheng E; Zhang Q; Dunbar KB; Theiss A; Pham TH; Wang DH; Watanabe T; Fujiwara Y; Arakawa T; Spechler SJ; Souza RF
Cell Mol Gastroenterol Hepatol; 2016 Jul; 2(4):439-453. PubMed ID: 27777967
[TBL] [Abstract][Full Text] [Related]
11. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
12. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
14. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
17. Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples.
Newell F; Patel K; Gartside M; Krause L; Brosda S; Aoude LG; Loffler KA; Bonazzi VF; Patch AM; Kazakoff SH; Holmes O; Xu Q; Wood S; Leonard C; Lampe G; Lord RV; Whiteman DC; Pearson JV; Nones K; Waddell N; Barbour AP
BMC Med Genomics; 2019 Feb; 12(1):31. PubMed ID: 30717762
[TBL] [Abstract][Full Text] [Related]
18. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
19. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.
Matsuzaki J; Suzuki H; Tsugawa H; Watanabe M; Hossain S; Arai E; Saito Y; Sekine S; Akaike T; Kanai Y; Mukaisho K; Auwerx J; Hibi T
Gastroenterology; 2013 Dec; 145(6):1300-11. PubMed ID: 23933602
[TBL] [Abstract][Full Text] [Related]
20. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
Lin L; Bass AJ; Lockwood WW; Wang Z; Silvers AL; Thomas DG; Chang AC; Lin J; Orringer MB; Li W; Glover TW; Giordano TJ; Lam WL; Meyerson M; Beer DG
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4251-6. PubMed ID: 22375031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
